English French German Italian Portuguese Russian Spanish

1

One Pharma Ltd | Leading Pharmaceuticals in Bangladesh - Super User
Super User

Super User

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Sunday, 16 October 2016 04:07

Ozink-B

Ozink-B

(Zinc & Vitamin B Complex Syrup)

 

Presentation

Ozink-B syrup: Each 5 ml syrup contains Zinc Sulfate Monohydrate USP 27.45 mg equivalent to Elemental Zinc 10 mg, Thiamine Hydrochloride (B1) BP 5 mg, Riboflavin 5-Phosphate Sodium BP 2.74 mg equivalent to Riboflavin (B2) 2 mg, Pyridoxine Hydrochloride (B6) BP 2 mg, Nicotinamide (B3) BP 20 mg.

 

Description

Ozink-B is a special preparation of B-Vitamins and Zinc.

 

Indications

Ozink-B is indicated for the treatment and prevention of B-vitamins and Zinc deficiencies. B-vitamins are needed to release energy from food. They play an important role in ensuring healthy brain and nerve function, formation of healthy red blood cells (RBC) in children & adults. They are specially required for healthy growth and development of children. Zinc is necessary to maintain a healthy immune system. It ensures normal growth & sexual development of children. It is further necessary for the growth and maintenance of muscles.

 

Dosage & Administration

Ozink-B syrup

Adults: 10 ml (1 measuring cup) 2 to 3 times daily or as recommended by the physician.

Children: 10 ml (1 measuring cup) 1 to 3 times daily or as recommended by the physician.

Infants: 5 ml (1/2 measuring cup) 1 to 2 times daily or as recommended by the physician.

 

Side Effect

Ozink-B is generally well tolerated.

 

Contraindication

Ozink-B is contraindicated in patients with a known hypersensitivity to any of the ingredients of this product.

 

Use in Pregnancy & Lactation

Recommended.

 

Overdose

In case of overdosage, initially epigastric pain, diarrhoea and vomiting can occur. Should seek emergency medical attention immediately. Initially an emetic should be given and then gastric lavage and general supportive measures should be employed.

 

Storage

Store in a cool and dry place, keep away from light. Keep all medicines out of reach of children.

 

Commercial Pack

Ozink-B syrup 100 ml: Each amber PET bottle contains 100 ml syrup with a measuring cup.

Sunday, 16 October 2016 03:56

Onepro

Onepro

(Esomeprazole)

Presentation

Onepro 20 tablet: Each delayed release tablet contains Esomeprazole Magnesium Trihydrate BP equivalent to Esomeprazole 20 mg.

Onepro 40 tablet: Each delayed release tablet contains Esomeprazole Magnesium Trihydrate BP equivalent to Esomeprazole 40 mg.

 

Description

Esomeprazole (Onepro) is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ATPase in the gastric parietal cell. By acting specifically on the proton pump, Onepro blocks the final step in acid production, thus reducing gastric acidity.

 

 

Indications and Usage

Treatment of Gastroesophageal Reflux Disease (GERD)

Healing of Erosive Esophagitis

Maintenance of Healing of Erosive Esophagitis

Symptomatic Gastroesophageal Reflux Disease

H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence

Zollinger-Ellison Syndrome

Acid Related Dyspepsia

Duodenal and Gastric Ulcer

 

Dosage and Administration

Tablet: The recommended adult dosages are outlined in the table below. Onepro delayed release tablet/capsule should be swallowed whole and taken at least one hour before eating.

The majority of patients are healed within 4 to 8 weeks. For patients who do not heal after 4-8 weeks, an additional 4-8 weeks of treatment may be considered.

**If symptoms do not resolve completely after 4 weeks, an additional 4 weeks of treatment may be considered.

 

Use in Pregnancy and Lactation

In Pregnancy: Pregnancy Category B. This drug should be used during pregnancy only if clearly needed.

 

In Lactation: The excretion of Esomeprazole in milk has not been studied. As Esomeprazole is likely to be excreted in human milk, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

 

Side-effects

In general, Esomeprazole was well tolerated in both short- and long-term clinical trials. The most frequently occurring adverse events (≥1%) are headache and diarrhea. Nausea, flatulence, abdominal pain, constipation and dry mouth occurred at similar rates among patients taking Esomeprazole.

 

Contraindications

Esomeprazole is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted Benzimidazoles.

 

Precautions

Symptomatic response to therapy with Esomeprazole does not preclude the presence of gastric malignancy. Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with omeprazole, of which Esomeprazole is an enantiomer.

 

Drug Interactions

Drug interaction studies have shown that Esomeprazole does not have any clinically significant interactions with Phenytoin, Warfarin, Quinidine, Clarithromycin or Amoxicillin.  Esomeprazole inhibits gastric acid secretion. Therefore, Esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, Ketoconazole, Iron salts and Digoxin). Coadministration of oral contraceptives, Diazepam, Phenytoin or Quinidine did not seem to change the pharmacokinetic profile of Esomeprazole.

 

Commercial Pack

Onepro 20 tablet: Each box contains 6 Alu-Alu blister strips of 10 tablets.

Onepro 40 tablet: Each box contains 3 Alu-Alu blister strips of 10 tablets.

Sunday, 16 October 2016 03:21

Onefix

CapsulOnefix

(Cefixime)

Presentation

Onefix 200 Capsule: Each capsule contains Cefixime Trihydrate USP equivalent to Cefixime 200 mg.

Onefix 400 Capsule: Each capsule contains Cefixime Trihydrate USP equivalent to Cefixime 400 mg.

Onefix 30 ml Powder for Suspension: After reconstitution according to direction, each 5 ml suspension contains Cefixime Trihydrate USP equivalent to Cefixime 100 mg.

Onefix 50 ml Powder for Suspension: After reconstitution according to direction, each 5 ml suspension contains Cefixime Trihydrate USP equivalent to Cefixime 100 mg.

 



Description:

Cefixime is a semi-synthetic, broad spectrum cephalosporin antibiotic of third generation for oral administration. It is a bactericidal antibiotic, kills bacteria by interfering in the synthesis of the bacterial cell wall. Cefixime is highly stable in the presence of beta-lactamase enzymes. Cefixime has marked in-vitro bactericidal activity against a wide variety of Gram-positive and Gram-negative organisms including beta lactamase producers.

Clinical efficacy of Cefixime has been demonstrated in infections caused by commonly occurring pathogens including Gram-positive organism Streptococcus pneumoniae, Streptococcus pyogenes, Gram-negative organism Escherichia coli, Proteus mirabilis, Klebsiella spp., Haemophilus influenzae (beta-lactamase positive and negative), Moraxella catarrhalis (beta-lactamase positive and negative), Salmonella typhi and Enterobacter species.

 

Indications and Uses:

Onefix is indicated in the following infectious diseases -

Respiratory Tract Infections:

Pneumonia

Sinusitis

Pharyngitis and Tonsillitis

Acute Bronchitis and Acute Exacerbations of Chronic Bronchitis (AECB)

Otitis Media

Typhoid Fever

Urinary Tract Infection

Uncomplicated gonorrhea (cervical/urethral)

 

Dosage and Administration:

The usual treatment of Onefix is 7 days. This may be continued for up to 14 days according to the severity of infection.

Side-effects

Cefixime is generally well tolerated. The majority of adverse reactions observed in clinical trials are mild and self limiting in nature.

Gastro-intestinal disturbance: Diarrhoea (if severe diarrhoea occurs, Cefixime should be discontinued), changes in the color of stool, nausea, abdominal pain, dyspepsia, vomiting, flatulence have been reported.

CNS disturbances: Headache, dizziness.

Others: Hypersensitivity reactions which usually subsided upon discontinuation of therapy; infrequent and reversible hematological changes; elevation of serum amylase.

 

Precautions

Cefixime should be prescribed with caution in individuals with a history of gastrointestinal diseases, particularly colitis.  Dosage adjustment is only necessary in severe renal failure (creatinine clearance < 20 ml/min)

 

Use in Pregnancy and Lactation

Pregnancy: Pregnancy category B. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Lactation: It is not known whether Cefixime is excreted in human milk. Consideration should be given to discontinuing nursing temporarily during treatment with this drug.

 

Use in Elderly

No special precautions are necessary. No dosage adjustment is required for elderly.

 

Contraindication

Patients with known hypersensitivity to Cefixime or cephalosporin group of drugs.

 

Drug Interactions

Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when Cefixime is administered concomitantly. Drug monitoring may be of assistance in detecting alterations in carbamazepine plasma concentrations.

Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.

 

Direction for Reconstitution of Suspension

uTo prepare 50 ml suspension, 30 ml boiled and cooled water is required.

uTo prepare 30 ml suspension, 20 ml boiled and cooled water is required.

 

Tap the bottle several times to loosen powder contents prior to reconstitution. Add approximately half of the total amount of water and shake well. Add remainder of water, and then shake again.

Note:  Shake the suspension well before each use. Keep the bottle tightly closed. The reconstituted suspension should be stored in a cool and dry place, preferably in refrigerator and unused portion should be discarded after 14 days.

 

Overdosage

Gastric lavage may be indicated; otherwise, no specific antidote exists. Cefixime is not removed in significant quantities from the circulation by hemodialysis or peritoneal dialysis. Adverse reactions in small numbers of healthy adult volunteers receiving single doses up to 2 g of Cefixime did not differ from the profile seen in patients treated at the recommended doses.

 

Commercial Pack

Onefix 200 Capsule: Box containing 2 Alu-Alu blister strips of 6 capsules.

Onefix 400 Capsule: Box containing 2 Alu-Alu blister strip of 4 capsules.

Onefix 30 ml Powder for Suspension: Bottle containing powder for the preparation of 30 ml suspension.

Onefix 50 ml Powder for Suspension: Bottle containing powder for the preparation of 50 ml suspension.

 

Sunday, 16 October 2016 03:17

Onecof

 

 

 

Onecof

Ambroxol

 (Presentation)


Onecof Syrup: Each 5 ml syrup contains Ambroxol hydrochloride BP 15 mg.

 

Description

Ambroxol is the active metabolite of Bromhexine and it has a greater bronchosecretolytic effect than Bromhexine. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency. Beside these, Ambroxol also exhibits anti-oxidant activity. Long-term use is possible because of the good tolerability of the preparation.

 

Indications

Acute and chronic diseases of respiratory tracts associated with viscid mucus

including acute and chronic bronchitis

Productive cough

Inflammatory diseases of Rhinopharyngeal tract (e.g. Laryngitis, Pharyngitis, Sinusitis and Rhinitis)          

Asthmatic bronchitis, Bronchial asthma with difficult departure of mucus

Bronchiectasis

Chronic pneumonia

 

Dosage and Administration

Average daily dose (preferably after meal):

 

 

Side-effects

Gastrointestinal side-effects like epigastric pain, gastric fullness may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema may occur.

 

Precautions

Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.

 

Use in Pregnancy and Lactation

Pregnancy: Teratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use during pregnancy, especially in the 1st trimester.

Lactation: Safety during lactation has not been established yet.

 

Contraindications

Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.

 

Drug Interactions

Ambroxol has no interaction with cardioactive glycosides, corticosteroids, bronchodilators, diuretics and antibiotics (normally used in the treatment of bronchopulmonary affections). But Ambroxol should not be taken simultaneously with antitussives (e.g. Codeine) because mucus, which has been liquefied by Ambroxol, might not be expectorated.

 

Commercial Pack

Onecof Syrup: Each PET bottle contains 100 ml syrup and a measuring cup.

 

 

 

Sunday, 16 October 2016 03:11

NX-1

NX-1

(Naproxen)

 

Presentation

NX-1 Tablet: Each enteric coated tablet contains Naproxen Sodium USP equivalent to Naproxen USP 500 mg.

 

Description

Naproxen is a nonsteroidal anti-inflammatory drug with analgesic and antipyretic properties. Naproxen works by reducing the levels of prostaglandins, chemicals that are responsible for pain, fever and inflammation. Naproxen blocks the enzyme that makes prostaglandins (cyclooxygenase), resulting in lower concentrations of prostaglandins. As a consequence, inflammation, pain and fever are reduced.

 

Indications and Uses

Naproxen is indicated for its anti-inflammatory and analgesic action in the treatment of rheumatoid arthritis, osteoarthritis (degenerative arthritis), ankylosing spondylitis, juvenile rheumatoid arthritis, acute gout, acute musculoskeletal disorders, post-operative pain and dysmenorrhoea. It is also indicated in the relief of mild to moderate pain, and for the treatment of tendonitis and bursitis.

 



Dosage and administration

Adults

For rheumatoid arthritis, osteoarthritis and ankylosing spondylitis

The usual dose is 500-1000 mg per day taken in 2 doses at 12 hours intervals after meals.

For acute gout

750 mg should be given initially, followed in 8 hours with 500 mg, and thereafter 250 mg at 12 hours intervals until the attack has passed.

For dysmennorhoea

500 mg should be given initially, followed by 250 mg at 6-8 hour intervals for up to 5 days.

For analgesia and acute muscular skeletal disorders

500 mg should be given initially, followed by 250 mg at 6-8 hour intervals.

Children over 5 years

For juvenile rheumatoid arthritis

10mg/kg/day given as 2 divided doses at 12 hour intervals.

 

Contraindications

The drug is contraindicated in patients who have had allergic reactions to Naproxen. It is also contraindicated in patients in whom aspirin or other nonsteroidal anti-inflammatory/analgesic drugs induce the syndrome of asthma, rhinitis, and nasal polyps. Both types of reactions have the potential of being fatal.

 

Precautions

Serious GI toxicity such as bleeding, ulceration, and perforation, can occur at any time, with or without warning symptoms, in patients treated chronically with NSAID therapy. Although minor upper GI problems, such as dyspepsia, are common, usually developing early in therapy, physicians should remain alert for ulcerations and bleeding in patients treated chronically with NSAIDs even in the absence of previous GI tract symptoms.

 

Side-effects

The most common side effects from Naproxen are rash, ringing in the ears, headaches, dizziness, drowsiness, abdominal pain, nausea, diarrhea, constipation, heartburn, fluid retention and shortness of breath. Naproxen also may cause stomach and intestinal bleeding and ulcers.

 

Use in pregnancy and lactation

Pregnancy: Pregnancy Category C.

Naproxen should be used during pregnancy only if the potential benefits justify the potential risks to the fetus.

Nursing mother: The Naproxen has been found in the milk of lactating women. Because of the possible adverse effects of prostaglandin-inhibiting drugs on neonates, use in nursing mothers should be avoided.

 

Drug interactions

Naproxen may increase the blood levels of lithium by reducing the excretion of lithium by the kidneys. Increased levels of lithium may lead to lithium toxicity.

Naproxen may reduce the blood pressure lowering effects of blood pressure medications.

When naproxen is used in combination with aminoglycosides (e.g., gentamicin) the blood levels of the aminoglycoside may increase. This may lead to more aminoglycoside-related side effects.

Individuals taking anticoagulants (e.g. Warfarin) should avoid naproxen because naproxen also thins the blood, and excessive blood thinning may lead to bleeding.

 

Overdosage

Naproxen overdosage may be characterized by drowsiness, heartburn, indigestion, nausea, or vomiting. In animals 0.5 g/kg of activated charcoal was effective in reducing plasma levels of Naproxen. Hemodialysis does not decrease the plasma concentration of Naproxen.

 

Commercial pack

NX-1 Tablet: Each box contains 3 blister strips of 10 tablets.

Sunday, 16 October 2016 03:04

Nevrona

Nevrona

(Vitamin B1, B6 & B12)

 

Presentation

Nevrona tablet: Each tablet contains Thiamine Mononitrate BP (100 mg), Pyridoxine Hydrochloride BP (200 mg), Cyanocobalamin BP (200 mcg).

 

Description

Nevrona is a special preparation of vitamin B1, B6 and B12. The vitamins B1, B6 and B12 are indispensable for a normal course of the nervous metabolism.

 

 

 

Indication & Uses

Nevrona is indicated for the treatment of B1, B6 and B12 deficiency syndrome. It is also indicated in  the treatment of:

 

 

Dosage and Administration

Tablets may be administered in a dose of 1 to 3 tablets per day or as directed by the physician.

 

Side Effects

Generally well tolerated. However, a few allergic reactions may be seen.

 

Precautions

Cyanocobalamin should not be given before a diagnosis has been fully established because of the possibility of masking symptoms of subacute degeneration of the spinal cord. Cyanocobalamin is not a suitable form of Vitamin B12 for the treatment of optic neuropathies associated with raised plasma concentrations of cyanocobalamin.

 

Use in pregnancy & lactation

Oral tablet form is recommended but injectable preparation is not recommended due to presence of benzyl alcohol.

 

Contraindications

Should not be used in the patients on Levodopa therapy and hypersensitivity to any of the active ingredients.

 

Drug Interactions

No such drug interactions have been reported.

 

Overdosage

If there is known overdose then treatment is symptomatic and supportive.

 

Commercial Pack

Nevrona Tablet: Each box contains 3 blister strips of 10 tablets.

Sunday, 16 October 2016 02:54

Dantron

Dantron

(Ondansetron)

 

Presentation

Dantron Tablet: Each film coated tablet contains Ondansetron Hydrochloride Dihydrate BP 9.977 mg equivalent to Ondansetron 8 mg.

Dantron Syrup: Each 5 ml syrup contains Ondansetron Hydrochloride Dihydrate BP equivalent to Ondansetron 4 mg.

 

Description

Ondansetron is a selective 5-HT3 receptor antagonist. While its mechanism of action has not been fully characterized, Ondansetron is not a dopamine-receptor antagonist. Serotonin receptors of the 5-HT3 type are present both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. It is not certain whether Ondansetron's antiemetic action is mediated centrally, peripherally, or in both sites. However, cytotoxic chemotherapy appears to be associated with release of serotonin from the enterochromaffin cells of the small intestine.

 

Indications and Uses

1. Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including Cisplatin ≥ 50 mg/m2

2. Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy

3. Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen

4. Prevention of post-operative nausea and/or vomiting

5. Nausea-vomiting associated with pregnancy

6. Nausea-vomiting associated with gastroenteritis

 

Dosage and Administration

 

Contraindications

Ondansetron is contraindicated for patients known to have hypersensitivity to the drug.

 

Precautions

Ondansetron is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction. The use of Ondansetron in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and/or gastric distension.

 

Side-effects

Generally Ondansetron is well tolerated. However few side effects including headache, diarrhoea, fatigue, dizziness and constipation may be seen after Ondansetron is administered.

 

Use in pregnancy & lactation 

Pregnancy: Pregnancy category B.

Nursing mother: It is not known whether Ondansetron is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Ondansetron is administered to a nursing woman.

 

Drug Interactions

The following drugs should be used with caution when concomitantly used with Ondansetron:

Phenytoin, Carbamazepine, Rifampicin & Tramadol.

 

Overdosage

There is no specific antidote for Ondansetron overdose. Hypotension (and faintness) occurred in a patient that took 48 mg of Ondansetron tablets.

 

Commercial Pack

Dantron Tablet: Each box contains 3 blister strips of 10 tablets.

Dantron Syrup: Each bottle contains 50 ml Syrup.

Thursday, 08 September 2016 09:29

Tilmicosin

Tilmicosin

Composition

Each 100 ml oral solution contains

Tilmicosin Phosphate 250 gm.

Pharmacology

Tilmicosin is a broad-spectrum bacteriostatic macrolide antibiotic synthesized from tylosin. It has an antibacterial spectrum that is predominantly effective against Mycoplasma, Pasturella and Haemophilus spp. and various Gram-positive organisms such as Corynebacterium spp. It is believed to affect bacterial protein synthesis through binding to 50S Ribosomal subunits. Cross-resistance between Tilmicosin and other macrolide antibiotics has been observed.

Indications

For treatment of bacterial disease caused by microorganisms susceptible to Tilmicosin.

Poultry: Mycoplasmosis (Mycoplasma gallisepticum, Mycoplasma synoviae).

Dosage and Administration

Poultry: Dilute at the rate of 1 ml of the product in 3 L of drinking water and administer for 3~5 consecutive days.

Packing

●  Each HDPE bottle contains 100 ml, 250 ml oral solution.

Thursday, 08 September 2016 09:26

Yuccamax-NH

Yuccamax NH

Content per L

Yucca extract            65,000 mg

Formic acid               85,000 mg

Phosphoric acid      1,50,000 mg

Propionic acid         1,00,000 mg

Species

Poultry and cattle.

Indications

A premix of organic acids associated with saponins of vegetal extract with antiureasic activity, a completely natural product with no withdrawal period.

Acidifying activity: Creates an anti-bacterial barrier at the level of the stomach. Helps to improve the digestion & stimulate intestinal motility. Controls the multiplication of the intestinal flora.

Antiureasic activity: Avoids the formation of ammonia at intestinal level, achieving an improved environment. It also protects the liver, improves intestinal absorption and natural digestion. Helps to avoid disorders like Colibacillosis, Hepatic intoxication by ammoniemia, presence of undigested feed in faeces, nutritional diarrhoea with damp bedding.

Dosage & Administration

Shake well before use. Administer in the drinking water at the dose of 1 ml/7-8 L of water. (A continuous maintenance dose from 0.5 to 1 ml/10 L of water can be used).

Storage

Keep well sealed in a cool, dry place, protected from light. This is an animal feed additive and not for human use.

Commercial Pack

100 ml, 500 ml.

Thursday, 08 September 2016 09:21

Vitaon-E-Sel Sol

Vitaon E-Sel Sol

Composition

Each 100 ml oral solution contains

Vitamin E             10,000 mg

Selenium                             50,000 mcg

Indications

Poultry: It is indicated to Nutritional Muscular Dystrophy/White Muscle Disease, Enzootic Paralysis, Crazy Chick disease, Encephalomalacia, Exudative diathesis, Ascites etc. Helps to increase egg production & hatchability. During Vaccination to increase antibody production & promote immunity. Vitamin E acts as anti-oxidant & protects cells from destroy. Vitamin E enhances immunity by producing anti-body.

Cattle, Horses, Goat, Sheep: It should use during pregnancy, lactating and growing animals. Any kind of Vitamin-E and/or Selenium deficiency. Vitamin E helps in proper development of genital organs and enhances its activity.

Dosage and Administration

Poultry: 1 ml per 2-4 litres of drinking water for 5-7 days.

Cattle, Horses, Goat, Sheep: 1-2 ml/10 kg body weight/Day for 5-7 days.

or as directed by the registered Veterinarian.

Side Effects

There is no prominent side effect of this drug while used in recommended dosage.

Contraindication

The drug should not be used in animal hypersensitive to any of its active ingredients.

Storage

Store below 30º C in a cool and dry place. Protect from Sun light. Do not refrigerate.

Precautions for use

1. Keep out of the reach of children.

2. Withdrawal period: Not Applicable.

3. After opening, use the product as soon as possible.

4. Keep the indicated storage conditions to avoid change of stability and effectiveness.

Commercial Pack

Each HDPE bottle contains 100 ml, 500 ml, 1000 ml, 2000 ml, 5000 ml oral solution.

Page 1 of 4
FacebookTwitterGoogle Bookmarks